CARA News Alert Cara Therapeutics Inc. (CARA) 8.98 09/19/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 19, 2014 at 5:49 PM

Cara Therapeutics Inc. (CARA) 8.98 $CARA

Cara Therapeutics to Sponsor Symposium at American Academy of Pain Management 2014 Annual Clinical Meeting
GlobeNewswire - Wed Sep 17, 8:28AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced it is sponsoring and participating in a lunch symposium titled, "Kappa: Myths / misconceptions, and moving beyond Mu," at the 25 Annual Clinical Meeting of the American Academy of Pain Management. Leading pain experts will discuss the evolving medical and regulatory climate around mu-opioids and how kappa agonists may become an important treatment option. Experts will also discuss the Phase 2 data from Cara's clinical program of CR845, a peripherally acting kappa receptor agonist for acute pain, as well as the future of analgesia.

Cara Therapeutics Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the second quarter ended June 30, 2014.

Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus
GlobeNewswire - Wed Aug 06, 7:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, today announced the dosing of the first dialysis patients in a Phase II trial of an intravenous formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of uremic pruritus. The company expects to report top-line data from this trial in the first half of 2015.

Cara Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, August 7, 2014, at 4:30 p.m. ET to report second quarter 2014 financial results and provide a corporate update.

Cara Therapeutics Initiates Human Abuse Liability Trial of CR845
GlobeNewswire - Thu Jul 31, 7:09AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting peripheral kappa opioid receptors, today announced the initiation of a human abuse liability (HAL) trial of an intravenous formulation of its peripherally-selective kappa opioid agonist, CR845. The company expects to report top-line data from this trial in the fourth quarter of 2014.

Cara Therapeutics receives milestone payment for completing its Phase 1 single and multiple ascending dose trial of IV CR845 in Japanese population
M2 - Thu Jul 17, 8:11AM CDT
Biopharmaceutical company Cara Therapeutics (NasdaqGM:CARA) revealed on Wednesday the receipt of a USD500,000 milestone payment from Maruishi Pharmaceutical Company for the completion of its Phase 1 clinical trial of the IV formulation of CR845 in Japan.

Cara Therapeutics Earns Milestone Payment From Maruishi Pharmaceutical for Completion of Phase 1 Clinical Trial of I.V. CR845 in Japan
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that it has earned a $500,000 milestone payment from Maruishi Pharmaceutical Company, Ltd., for the completion of Maruishi's Phase 1 clinical trial of the I.V. formulation of Cara's novel kappa opioid agonist, CR845, in Japan.

3 Stocks Rising on Unusual Volume
at The Street - Tue Jul 01, 7:13AM CDT
Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Cara Therapeutics Announces Appointment of Robert Medve, M.D., as Chief Medical Officer
GlobeNewswire - Tue Jun 24, 7:07AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that Dr. Robert Medve has been named Chief Medical Officer, effective immediately. Dr. Medve will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.

Strength Seen in Cara Therapeutics Inc. (CARA) as Stock Rallies 19.60% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 7:44AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as the company saw its shares surge over 19% on the day.

Why Cara Therapeutics Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 20, 12:38PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cara Therapeutics , a clinical-stage...

Enteris BioPharma Oral Peptide Delivery Technology Enables Key Clinical Milestone for Acute and Chronic Pain Drug
PR Newswire - Fri Jun 20, 7:10AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced that its development partner, Cara Therapeutics (Nasdaq: CARA) has dosed the first subjects in a further Phase 1a/1b clinical trial of a tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain.

Cara Therapeutics Initiates Phase Ia/Ib Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
GlobeNewswire - Wed Jun 18, 7:08AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the dosing of the first subjects in a Phase Ia/Ib clinical trial of an oral tablet formulation of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. The company expects to report top-line pharmacokinetic, safety and biomarker data in the fourth quarter of 2014.

Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.

Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2013.

Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, March 27, 2014, at 4:30 p.m. ET to report fourth quarter and full year 2013 financial results and provide a corporate update.

'Mad Money' Lightning Round: No Fan of Lionsgate
at The Street - Thu Mar 13, 5:00AM CDT
Cramer is cautious on Cara Therapeutics but thinks DaVita is a terrific health care play.

Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.

New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

AI Deepfakes Met Their Match: IC-Corp's New Patent

The Deepfake Fraud Reality Slap You know, in a world where you can't trust your own eyes on a video call, trust gets a bit sketchy, right? Imagine this scenario—an unsuspecting finance employee, surrounded by familiar faces and voices, only to wind up sending $25.6 million to fraudsters who weren't even real. A chilling real-world example from January 2024, courtesy of...

Investor Scrutiny Intensifies Over M&A Deals at SGRY, RRC, EQT

When Insiders Seem to Benefit More Ah, mergers and acquisitions—it's the oldest tango in the business world. But today, we've got some footwork that might trip up the small fry. Halper Sadeh LLC, the investor rights bulldogs, are sniffing around Surgery Partners, Range Resources, and EQT. Their quest? To uncover whether the big dogs are playing unfairly with...

Mission Bancorp Hits Record Earnings, Extends Buyback

Record-Breaking Quarter Amid Challenging Times When Mission Bancorp's earnings hit the tape today, the numbers were enough to catch anyone's eye—$9.2 million in net income for Q3 2026, a 6% increase from last year. That's not small potatoes, especially considering the economic fog we're navigating through. AJ Antongiovanni, holding the reins as CEO, credits the bank's...

Columbia Distributing Expands to Alaska: A Growth Move

Alaska's Entry: Columbia's New Frontier When Columbia Distributing dives into a new territory, you know they're serious about growth. This latest move sees them planting their flag in Alaska, finally completing a strategic vision that's been brewing for a while. Four-State Strategy Comes to Fruition The transaction with Republic National Distributing Company (RNDC) is no...

ADSQUIRE Dominates 2026 with Jaw-Dropping ROI and Award

ADSQUIRE's Phenomenal ROI Grabs Industry Spotlight Just when you think the PPC world has seen it all, ADSQUIRE steps in and flips the script. With a jaw-dropping 8,000% return on investment (ROI) from a mere $4,000 ad spend in just one month, they've taken the PPC Agency of the Year title at the 2026 Search Engine Land Awards. For a Philadelphia-based agency focused on...

Duke Energy's Battle Against Energy Vampires Heats Up

Unplugging Hidden Electricity Drains Ever wonder why your electric bill has been sneakily creeping up? You might think it's just the AC running full blast or lights left on, but surprise, surprise—there’s a whole army of “energy vampires” quietly sucking the juice out of your home. Duke Energy Florida is drawing attention to this sneaky leak, especially around...

Brennan Takes a Swing: Barrasso Endorsement in Hand

Brennan Shakes Up Wyoming Politics You don’t need a crystal ball to see the chess game unfolding in Wyoming's political landscape. Shannon Brennan's bid for the House seat in Teton County's District 23 got a heavy artillery boost today. She’s landed the endorsement of Senator John Barrasso, none other than the Senate Majority Whip and a formidable player in the Senate...

ROKAE Hits 10,000 Delivery Mark for Robotic Arms

ROKAE's Big 10K: A Milestone Worth Noting Alright, if you've been around the block as long as I have, you know the robotics game isn't just about making cool gadgets—it's about hitting those serious deployment numbers. ROKAE Robotics just rolled its 10,000th humanoid force-controlled arm off the line in Shandong, and this ain't just another notch on their belt. This...

Revamp Preschool Questions for Richer Conversations

Preschoolers, those tiny agents of chaos, come home with stories that you'd need a magnifying glass to find. Ask 'em "How was school?" and you're met with blank stares or a one-liner. Tami Nix of Archway Academy has been at this game for over 40 years, and she's got a trick or six up her sleeve. Ditch the Generic: Get Specific Yep, those generic questions are about as...